25 September 2024
Incanthera plc
("Incanthera" the "Company")
Notice of
Annual General Meeting 2024 and Posting of Annual Report and
Accounts
Incanthera plc (AQSE:
INC), the company focused on innovative technologies in dermatology
and oncology, confirms that the Annual Report and Accounts for the
year ended 31 March 2024, and the Notice of Annual General Meeting
("AGM") with accompanying Form of Proxy has been posted to
shareholders and to the Company's website today.
These documents are
available, in electronic form, for download on the Company's
website: https://www.incanthera.com/media/144901/Incanthera-2024-NoM.pdf
https://www.incanthera.com/media/144904/Incanthera-ARA-2024.pdf
Incanthera's AGM will
be held at 11:00 am on Thursday,17 October 2024 at the
offices of Gateley Plc, 1 Paternoster Square, London EC4M
7DX.
In order to ensure
that shareholders are able to follow the proceedings of the AGM
without attending in person, the Company will provide access online
via the Investor Meet Company platform. However, please
note that shareholders will not be able to vote online at the AGM
via the platform and are therefore requested to submit their votes
via proxy, as early as possible.
Shareholders are
invited to submit any questions for the Board to consider.
Questions can be pre submitted ahead of the AGM via the Investor
Meet Company Platform up until 16 Oct 2024, 09:00 BST, or submitted
at any time during the AGM itself.
Shareholders that wish
to attend the AGM remotely should register for the event in advance
by using the following link:
https://www.investormeetcompany.com/incanthera-plc/register-investor
Investors who already
follow INCANTHERA PLC on the Investor Meet Company platform will
automatically be invited.
The Board will respond
to key questions during the meeting and will provide such answers
on its website thereafter.
For further
information please contact:
Notes to Editors
About Incanthera plc
Incanthera
is a specialist company focused on innovative technologies in
dermatology and oncology. It seeks to identify and develop
innovative solutions to current clinical, commercially relevant
unmet needs, utilising new technology from leading specialists and
academic institutions as well as its in-house development
team.
The Company
originated from the Institute of Cancer
Therapeutics ("ICT") at the University
of Bradford. Incanthera's strategy is to develop each
candidate in its portfolio from initial acquisition or discovery to
securing its future through commercially valuable partnerships at
the earliest opportunity in its development pathway.
For more
information on the Company please visit: www.incanthera.com
@incantheraplc